The U.S. Food and Drug Administration has approved Orchard Therapeutics’ Lenmeldy (atidarsagene autotemcel) as the first gene therapy for the treatment of children with metachromatic leukodystrophy (MLD).

Lenmeldy is a one-time, individualized single-dose infusion made from a patient’s own hematopoietic stem cells, which have been genetically modified to include functional copies of the ARSA gene that codes for the arylsulfatase A enzyme. It is indicated for presymptomatic late infantile, presymptomatic early juvenile, or early symptomatic early juvenile MLD.

The priority-review orphan drug approval was based on data from 37 children who received Lenmeldy. Compared with untreated children, Lenmeldy significantly reduced the risk for severe motor impairment or death.

All children with presymptomatic late infantile MLD treated with Lenmeldy were alive at 6 years of age versus only 58 percent of untreated children. Seven in 10 treated children (71 percent) were able to walk without assistance at 5 years of age, and 85 percent had normal language and performance IQ scores.

Children with presymptomatic early juvenile and early symptomatic early juvenile MLD showed slowing of motor and/or cognitive disease with Lenmeldy.

“MLD is a devastating disease that profoundly affects the quality of life of patients and their families. Advancements in treatment options offer hope for improved outcomes and the potential to positively influence the trajectory of disease progression,” Nicole Verdun, M.D., director of the Office of Therapeutic Products at the FDA, said in a statement.

“This approval represents important progress in the advancement and availability of effective treatments, including gene therapies, for rare diseases.”

Source: https://medicalxpress.com/news/2024-03-reveals-argonaute-syndromes-class-neurodevelopmental.html
GMP mRNA
Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Scientists develop potential stealth cancer therapy

Credit: ACS Central Science (2024). DOI: 10.1021/acscentsci.4c00559Sneaking by cancer's defenses, by disguising tumor-fighting antibodies inside the molecules cancer uses to nourish tumor growth, is the basis of a novel therapy from Yale Cancer Center researchers at...

read more

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE